<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569631</url>
  </required_header>
  <id_info>
    <org_study_id>BPN14770-CNS-203</org_study_id>
    <nct_id>NCT03569631</nct_id>
  </id_info>
  <brief_title>A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetra Discovery Partners</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tetra Discovery Partners</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, 2-period crossover study to explore the
      effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome.
      Subjects will receive both active treatment with BPN14770 capsules and matching placebo
      capsules in the course of the study. One treatment will be administered during each of the
      12-week study periods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 subjects will be enrolled. The study consists of a screening period of up to 28
      days prior to initial treatment, followed by two double-blind treatment periods, each 12
      weeks long. A final follow-up visit or phone contact for safety is planned one week after the
      conclusion of Period 2.

      Eligible subjects will be randomized in a blinded, balanced (1:1) fashion to receive either
      25 mg BPN14770 capsules or matching placebo capsules during Period 1, followed by the
      opposite treatment during Period 2. One capsule will be taken twice daily during both
      double-blind periods.

      Subjects will return to the clinic at the end of Weeks 2, 6, and 12 of each study period.
      Cognitive and behavioral evaluations will be repeated at Weeks 6 and 12 of each Period.
      Additionally, patients will be monitored for adverse events via a telephone call at the end
      of Week 1 of each Period, and one week following completion of Period 2 or following early
      discontinuation.

      During clinic visits, adverse effects will be assessed, and laboratory measures, vital signs,
      and ECGs will be performed. Suicidality risk will also be evaluated at each clinic visit; if
      a concern is detected, the subject will be referred for further evaluation and treatment.
      Cognitive and behavioral assessments will be performed during each clinic visit.
      Pharmacodynamic measures of CNS function will be obtained to evaluated effects of the drug in
      the brain. Pharmacokinetic samples will be collected to confirm that study drug is present
      and to estimate plasma exposure at Week 12 of each Period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Number of subjects with treatment-related adverse events as assessed by MedDRA</description>
  </primary_outcome>
  <other_outcome>
    <measure>NIH-TCB: NIH Toolbox Cognitive Battery for Intellectual Disabilities</measure>
    <time_frame>Change from Baseline to Week 6 and Week 12 of each Period for each of 7 assessments</time_frame>
    <description>A set of 7 cognition assessments administered on an iPad</description>
  </other_outcome>
  <other_outcome>
    <measure>KiTAP Test of Attentional Performance</measure>
    <time_frame>Change from Baseline to Week 6 and Week 12 of each Period</time_frame>
    <description>A set of 4 subtests designed in the form of short games</description>
  </other_outcome>
  <other_outcome>
    <measure>CGI-S: Clinical Global Impression-Severity</measure>
    <time_frame>Change from Baseline to Week 6 and Week 12 of each Period</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
  </other_outcome>
  <other_outcome>
    <measure>CGI-I: Clinical Global Impression-Improvement</measure>
    <time_frame>Change from Baseline to Week 6 and Week 12 of each Period</time_frame>
    <description>The CGI is a clinician-rated scale utilizing history from the caregiver and incorporating it into a clinical rating, first for severity, and then for clinical follow-up. The CGI-S will be used at the baseline assessment to judge symptom severity as 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill. The CGI-I will be used at the Week 8 and End of Treatment/Week 16 visits to judge the change in clinical impression as 1 = Very Much Improved; 2 = Much Improved; 3 = Minimally Improved; 4 = No Change; 5 = Minimally Worse; 6 = Much Worse; and 7 = Very Much Worse.</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS: Visual Analog Rating Scale</measure>
    <time_frame>Change from Baseline to Week 6 and Week 12 of each Period</time_frame>
    <description>The VAS will be used to measure the severity of three specific behavioral symptoms targeted in this study: behavior problems, language abilities, and eating behavior. For each behavior the caregiver is instructed to mark their impression of the behavior at the baseline visit and again at the Week 8 and End of Treatment/Week 16 visits. The calculated distance in cm between the visit marks thereby demonstrates whether each behavior stayed the same, improved, or worsened during the study and by how much. The scale is from 0 cm (defined as &quot;worst behavior&quot;) to 10 cm (&quot;behavior not a problem&quot;).</description>
  </other_outcome>
  <other_outcome>
    <measure>ABC: Aberrant Behavior Checklist</measure>
    <time_frame>Change from Baseline to Week 12 of each Period</time_frame>
    <description>The Aberrant Behavior Checklist (ABC) is a 58-item rating scale used to assess maladaptive behaviors across five original subscales: Irritability (15 items from 0-45), Social Withdrawal (16 items from 0-48), Stereotypy (7 items from 0-21), Hyperactivity (16 items from 0-48), Inappropriate Speech (4 items from 0-12). Additionally, Social Avoidance, a newly developed four-item subscale (from 0-12) of the ABC that captures core social avoidance aspects of Fragile X Syndrome is reported. All items on the ABC are rated from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate greater maladaptive behaviors. Differences between Baseline and Week 10 are used as an indicator of change.</description>
  </other_outcome>
  <other_outcome>
    <measure>ADAMS: Anxiety, Depression, and Mood Scale</measure>
    <time_frame>Change from Baseline to Week 12 of each Period</time_frame>
    <description>The ADAMS (Anxiety, Depression, and Mood Scale) is a 28-item behavior-based informant instrument designed to assess anxiety, depression and mood disorders in individuals with intellectual disability. Items are rated on a scale of 0 (&quot;behavior has not occurred, or is not a problem&quot;) to 3 (&quot;behavior occurs a lot, or is a severe problem&quot;). The scale is composed of 5 factors which address: Manic/Hyperactive Behavior, Depressed Mood, Social Avoidance, General Anxiety and Obsessive/Compulsive Behavior.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vineland-3 Rating Scale</measure>
    <time_frame>Change from Baseline to 12 of each Period</time_frame>
    <description>The VABS-III is a caregiver survey interview that measures the personal and social skills of individuals from birth through adulthood. It was designed to assess handicapped and non-handicapped persons in their personal and social functioning and is appropriate for individuals of all ages. The Adaptive Behavior Composite (ABC) score is calculated from the caregiver responses using age-adjusted scoring tables. ABC scores range from 20 to 160 and indicate low (20-70), moderately low (70-85), adequate (85-115), moderately high (115-130), or high (130-160) overall adaptive functioning.</description>
  </other_outcome>
  <other_outcome>
    <measure>ERP: Event Related Potentials</measure>
    <time_frame>Change from Baseline to Week 12 of each Period</time_frame>
    <description>An EEG (electroencephalogram) maps timing of a subject's responses to sounds heard in a headset.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eye Tracking</measure>
    <time_frame>Change from Baseline Week 12 of each Period</time_frame>
    <description>Subjects will view pictures shown on the screen. Each assessment begins with presentation of a scrambled face image followed immediately by its matched face image. Measurements include looking time to the eye region of interest (ROI), and number of fixations to the eye ROI, as well as pupil dilatation by pupilometry.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Fragile X Syndrome</condition>
  <condition>FXS</condition>
  <condition>Fra(X) Syndrome</condition>
  <arm_group>
    <arm_group_label>BPN14770</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules, one capsule taken twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPN14770</intervention_name>
    <description>25 mg BPN14770 capsules</description>
    <arm_group_label>BPN14770</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules to mimic 25 mg BPN14770 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is male aged 18 to 45 years, inclusive.

          2. Subject has Fragile X Syndrome with a molecular genetic confirmation of the full
             Fragile X Mental Retardation (FMR1) mutation (â‰¥200 CGG repetitions).

          3. Current treatment with no more than 3 prescribed psychotropic medications. Anti-
             epileptic medications are permitted and are not counted as psychotropic medications if
             they are used for treatment of seizures. Anti-epileptics for other indications, such
             as the treatment of mood disorders, count towards the limit of permitted medications.

          4. Permitted concomitant psychotropic medications must be at a stable dose and dosing
             regimen for at least 2 weeks prior to Screening and must remain stable during the
             period between Screening and the commencement of study medication.

          5. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks
             prior to Screening and must remain stable during the period between Screening and the
             commencement of study medication.

          6. Subjects with a history of seizure disorder who are currently receiving treatment with
             anti-epileptics must have been seizure-free for 3 months preceding Screening, or must
             be seizure-free for 3 years if not currently receiving anti-epileptics.

          7. Behavioral and therapy treatments/interventions must be stable for 4 weeks prior to
             Screening and must remain stable during the period between Screening and the
             commencement of study medication, and throughout the study. Minor changes in hours or
             times of therapy that are not considered clinically significant will not be
             exclusionary. Changes in therapies provided through a school program, due to school
             vacations, are allowed.

          8. Subject must be willing to practice barrier methods of contraception while on study,
             if sexually active. Abstinence is also considered a reasonable form of birth control
             in this study population.

          9. Subject has a parent, legal authorized guardian or consistent caregiver.

         10. Subject and caregiver are able to attend the clinic regularly and reliably.

         11. Subject is able to swallow tablets and capsules.

         12. For subjects who are not their own legal guardian, subject's parent/legal authorized
             guardian is able to understand and sign an informed consent form to participate in the
             study.

         13. If subject is his/her own legal guardian, he/she can understand and sign informed
             consent to participate in the study.

         14. If subject is not their own legal guardian, the subject provides assent for
             participation in the study, if the subject has the cognitive ability to provide
             assent.

        Exclusion Criteria:

          1. History of, or current cardiovascular, renal, hepatic, respiratory, gastrointestinal,
             psychiatric, neurologic, cerebrovascular, or other systemic disease that would place
             the subject at risk or potentially interfere with the interpretation of the safety,
             tolerability, or efficacy of the study medication. Common diseases such as mild
             hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C [Hgb A1C]
             &lt;6.5%), etc. are allowed per the investigator's judgment as long as they are stable
             and controlled by medical therapy that is constant for at least 4 weeks before
             randomization.

          2. Renal impairment, defined as serum creatinine &gt; 1.25 x ULN at screening

          3. Hepatic impairment, defined as ALT or AST elevation &gt; 2 x ULN at screening. Note:

             LFTs may be repeated after 1 week to evaluate return to acceptable limits; if LFTs
             remain elevated, subject is ineligible to participate.

          4. Clinically significant abnormalities, in the investigator's judgment, in safety
             laboratory tests, vital signs, or ECG, as measured during Screening.

          5. History of substance abuse within the past year, according to investigator assessment.

          6. Significant hearing or visual impairment that may affect the subject's ability to
             complete the test procedures.

          7. Concurrent major psychiatric condition (e.g., Major Depressive Disorder, Schizophrenia
             or Bipolar Disorder) as diagnosed by the investigator. Subjects with additional
             diagnosis of Autism Spectrum Disorder or Anxiety Disorder will be allowed.

          8. Subject has active diseases that would interfere with participation, such as acquired
             immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.

          9. Subject is planning to commence psychotherapy or cognitive behavior therapy (CBT)
             during the period of the study or had begun psychotherapy or CBT within 4 weeks prior
             to Screening.

         10. Subject is related to anyone employed by the sponsor, investigator, or study staff.

         11. Subject has BMI less than 18 or greater than 36.

         12. Subject has participated in another clinical trial within the 30 days preceding
             Screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D). Sci Rep. 2017 Nov 7;7(1):14653. doi: 10.1038/s41598-017-15028-x.</citation>
    <PMID>29116166</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphodiesterase Type 4D</keyword>
  <keyword>PDE4D</keyword>
  <keyword>Cognitive Dysfunction</keyword>
  <keyword>Neurocognitive Disorders</keyword>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>Fragile X</keyword>
  <keyword>FXS</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Cognition Disorders</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Nootropic Agents</keyword>
  <keyword>Developmental Disorder</keyword>
  <keyword>Autism</keyword>
  <keyword>Autistic Spectrum Disorder</keyword>
  <keyword>Genetic Disease</keyword>
  <keyword>Behavioral Disorder</keyword>
  <keyword>Learning Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

